<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230702058649N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-02-10</date_registration>
      <primary_sponsor>Mazandaran University of Medical Sciences</primary_sponsor>
      <public_title>Effects of Lavender and Rosemary Essential Oils on Sleep Quality and Mental Well-Being in Coronary Artery Disease Patients</public_title>
      <acronym></acronym>
      <scientific_title>Healing Aromas: The Effects of Lavender and Rosemary Essential Oils on Sleep Quality and Mental Well-Being in Coronary Artery Disease Patients: a Parallel Arm, Randomized, Controlled Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-02-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>148</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/71060</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Factorial, Purpose: Supportive, Randomization description: Eligible people will be selected by the available method and will be placed in three intervention groups and one control group using block randomization method. For this purpose, 37 blocks of 4 will be allocated using www.randomizer.org website, and each block will have 4 random numbers from 1 to 4. Then these blocks will be written on paper and sealed and then randomly one block will be chosen at each turn and people will enter the study in the order written on the paper. In fact, one block of four out of every 37 blocks of four will be randomly selected and the patients, as specified in the block, will divided into these groups: aromatherapy with lavender (1), aromatherapy with rosemary (2), simultaneous aromatherapy with these two aromas (3) and control (4). In this way, four patients (one patient in each group) will be examined each time. For the next time, another block is randomly selected and the patients are divided into one of the four study groups based on the selected block. Some blocks of four will be facing as follows: 2341, 1342, 1234, Blinding description: In this study, the data analyst and the researcher who evaluates the results will be blinded and unaware of the nature of the groups, but the nurse assessor (data collector) will not be blinded. For this purpose, first of all, bottles containing essential oils and distilled water, which are completely similar in appearance, will be provided to the nurse evaluator, and she will randomly give them to the samples. without the researcher and data analyst knowing the nature of the groupings. It should be noted that the distinctive smell of essential oils makes it difficult to blind the study participants.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Coronary Artery disease.</hc_freetext>
      <i_freetext>Intervention 1: First intervention group: Aromatherapy with lavender, samples will be exposed to the aromatic substance three times a day at 8 am, 3 pm and 10 pm for 20 minutes by pouring 4 drops of the relevant aromatic oil (provided by Barijesans Company) on a piece of gauze and attaching it to the patient's collar. This will be done for 30 consecutive days. Intervention 2: second intervention group: Aromatherapy with rosemary, samples will be exposed to the aromatic substance three times a day at 8 am, 3 pm and 10 pm for 20 minutes by pouring 4 drops of the relevant aromatic oil (provided by Barijesans Company) on a piece of gauze attached to the patient's collar. This will be done for 30 consecutive days. Intervention 3: The third intervention group: Simultaneous aromatherapy with rosemary and lavender, samples will be exposed to the aromatic substance three times a day at 8 am, 3 pm and 10 pm for 20 minutes by pouring 2 drops of lavender essential oil and 2 drops of rosemary essential oil (provided by Barijesans Company) on a piece of gauze attached to the patient's collar and this will be done for 30 consecutive days. Intervention 4: Control group: Samples will be exposed to the placebo substance three times a day at 8 am, 3 pm and 10 pm for 20 minutes by pouring 4 drops of saline solution on a piece of gauze and attaching it to the patient's collar and this will be done for 30 consecutive days.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All demographic information, sleep quality, depression and anxiety of the samples

When:
accessible from 2024

To whom:
The data will be accessible to researchers working in academic and scientific institutions.

Conditions:
The data will be used in secondary data analysis or meta-analysis studies.

Where to obtain:
Address of the University: The Headquarters of Mazandaran University of Medical Sciences and Health Services, the beginning of ValiAsr Highway (AJ), Sari
Postal code: 48157-33971
Contact phone numbers: 09811-33044000 and 09811-33044001
Contact number of Research and Technology Unit: 09811-34484800
Email of Research and Technology Unit: pajhoheshi@mazums.ac.ir
Assistant of Research and Technology Unit: Dr. Pedram Ebrahimnejad

How to obtain:
At first, official request will be sent from the applicant organization to Mazandaran University of Medical Sciences, and if there is no legal prohibition, the information will be provided to the researcher with the coordination and permission of the university's Research and Technology Unit.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Fatemeh Ahmadjani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.8 Keshavarz Alley, Keshavarz Blvd, Babol</address>
        <city>Babol</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۴۷۱۶۱۴۱۷۷۶</zip>
        <telephone>+98 11 3223 1149</telephone>
        <email>Fateme.Ahmadjanii@gmail.com</email>
        <affiliation>Mazandaran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Fateme Ahmadjani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No 161, Keshavarz8 Alley, keshavarz Blvd, ganjafrooz Road</address>
        <city>Babol</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4716141776</zip>
        <telephone>+98 11 3223 1149</telephone>
        <email>F.ahmadjani@mazums.ac.ir</email>
        <affiliation>Mazandaran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Being diagnosed with coronary artery Disease
Having no history of neuropsychiatric disease by self report
Having no history of taking psychiatric medications
Normal olfactory function
Not using benzodiazepines, sedatives and narcotics
No history of asthma
No history of allergies to plants or any seasonal allergies
Absence of severe pain causes sleep disturbance
Obtaining scores of greater than five from the PSQI Sleep quality questionnaire
Having an ejection fraction above 45%
Being able to read and write
Access to social media</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Acute pain at the time of completing the questionnaire
Any case that causes olfactory disorders during study
Showing an allergic reaction to the smell of essential oils
Showing discomfort with the smell of essential oils
Occurrence of life-threatening complications such as cardiopulmonary resuscitation</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>I20-I25</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Ischaemic heart diseases</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>N/A</i_code>
      <i_code>N/A</i_code>
      <i_code>N/A</i_code>
      <i_code>N/A</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>First intervention group: Aromatherapy with lavender, samples will be exposed to the aromatic substance three times a day at 8 am, 3 pm and 10 pm for 20 minutes by pouring 4 drops of the relevant aromatic oil (provided by Barijesans Company) on a piece of gauze and attaching it to the patient's collar. This will be done for 30 consecutive days.</i_keyword>
      <i_keyword>second intervention group: Aromatherapy with rosemary, samples will be exposed to the aromatic substance three times a day at 8 am, 3 pm and 10 pm for 20 minutes by pouring 4 drops of the relevant aromatic oil (provided by Barijesans Company) on a piece of gauze attached to the patient's collar. This will be done for 30 consecutive days.</i_keyword>
      <i_keyword>The third intervention group: Simultaneous aromatherapy with rosemary and lavender, samples will be exposed to the aromatic substance three times a day at 8 am, 3 pm and 10 pm for 20 minutes by pouring 2 drops of lavender essential oil and 2 drops of rosemary essential oil (provided by Barijesans Company) on a piece of gauze attached to the patient's collar and this will be done for 30 consecutive days.</i_keyword>
      <i_keyword>Control group: Samples will be exposed to the placebo substance three times a day at 8 am, 3 pm and 10 pm for 20 minutes by pouring 4 drops of saline solution on a piece of gauze and attaching it to the patient's collar and this will be done for 30 consecutive days.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Depression score in Cardiac Depression Scale (CDS). Timepoint: Before the intervention, 14 and 30 days after the start of the intervention. Method of measurement: Cardiac Depression Scale (CDS).</prim_outcome>
      <prim_outcome>Anxiety score in Hospital Anxiety and Depression Scale (HADS ). Timepoint: Before the intervention, 14 and 30 days after the start of the intervention. Method of measurement: Hospital Anxiety and Depression Scale (HADS ).</prim_outcome>
      <prim_outcome>Sleep quality score in Pittsburgh Sleep Quality Index (PSQI). Timepoint: Before the intervention, 14 and 30 days after the start of the intervention. Method of measurement: Pittsburgh Sleep Quality Index (PSQI).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mazandaran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-10-25</approval_date>
        <contact_name>Ethics committee of Mazandaran University of Medical Science</contact_name>
        <contact_address>No.8 Keshavarz Alley, Keshavarz Blvd, Babol Babol Mazandaran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
